Opaleye Management Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595855

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q1 2026 · 53 positions · Total reported value $739.73M · Top-10 concentration 63.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 13 new · 12 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +40.3% · vs SPY +25.5% · Prev Value $739.73M — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2026 13F filing, Opaleye Management Inc. disclosed 53 equity positions with a combined reported value of $739.73M. The filing implies a focused portfolio: its ten largest positions account for 63.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were HROW ($99.86M), LQDA ($88.82M), ETON ($70.58M). By sector, the heaviest allocations are Health Care 90.2%, Materials 1.9%. Versus the prior quarter, allocation shifted toward Other (+0.6pp) and away from Health Care (-0.8pp).

Versus the prior quarter, Opaleye Management Inc. opened 13 new positions, trimmed 12 and fully exited 8, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q1 2026 were EDIT ($4.76M), BDSX ($3.45M), NTLA ($3.14M).

Of the 8 positions fully exited versus the prior quarter, the largest were ALKS ($13.71M), GOSS ($8.43M), KPTI ($6.84M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • EDIT EDITAS MEDICINE INC · $4.76M
  • BDSX BIODESIX INC · $3.45M
  • NTLA Intellia Therapeutics, Inc. · $3.14M
  • LYEL LYELL IMMUNOPHARMA INC · $1.59M
  • NXTC NEXTCURE INC · $1.51M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · $1.05M
  • BBOT BridgeBio Oncology Therapeutic Inc · $476.87K
  • LBRX LB PHARMACEUTICALS INC · $357.72K

Fully Exited (vs previous quarter)

  • ALKS Alkermes Plc · prev qtr: $13.71M
  • GOSS GOSSAMER BIO INC · prev qtr: $8.43M
  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $6.84M
  • ZYME ZYMEWORKS INC · prev qtr: $2.87M
  • VTYX VENTYX BIOSCIENCES INC · prev qtr: $2.27M
  • GBIO GENERATION BIO CO · prev qtr: $1.76M
  • BBIO Bridgebio Pharma Inc · prev qtr: $1.40M
  • SLN SILENCE THERAPEUTICS PLC · prev qtr: $479.87K

Insider Transactions (Form 4)

Latest Opaleye Management Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-05 Buy Grace Therapeutics, Inc. 3,087 $1.77 SEC filing
2026-11-04 Buy Grace Therapeutics, Inc. 5,027 $1.80 SEC filing
2026-11-03 Buy Grace Therapeutics, Inc. 10,328 $1.79 SEC filing
2026-10-26 Buy Grace Therapeutics, Inc. 66,411 $1.77 SEC filing
2026-10-23 Buy Alpha Cognition Inc. 14,973 $8.23 SEC filing
2026-10-22 Buy Alpha Cognition Inc. 17,117 $8.33 SEC filing
2026-10-22 Buy Grace Therapeutics, Inc. 21,390 $1.93 SEC filing
2026-10-19 Buy Grace Therapeutics, Inc. 4,256 $1.88 SEC filing

All insider transactions →

Fund Profile

Opaleye Management Inc. is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 58 US equity positions with a combined value of $1.10B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-78700 (status: Approved), registered 2013-10-29
  • Regulatory AUM (Form ADV): $802.77M as of 2026-02-19
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 58 positions · $1.10B reported value (Q2 2026)
  • Top 10 holdings = 64.8% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 17.7%
  • Average position size: $19.04M

Sector Tilt

  • Health Care 90.7%
  • Materials 1.9%
  • Industrials 1.4%
  • (classified holdings cover 94% of value)

Quarterly Activity

  • Q2 2026: 13 new, 14 added, 12 reduced, 8 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious approach with a slight inclination towards growth in the healthcare sector. The addition of new positions in healthcare companies suggests an optimism in the sector's potential, while reductions in some holdings indicate selectivity and risk management. 2. Key Moves: - Added: IRON (DISC MEDICINE INC) with a significant increase of 103.1% in shares, MGTX (MeiraGTx Holdings plc) with a 67.2% increase in shares. - Reduced: LQDA (LIQUIDIA CORPORATION) by 3.8% in shares, HROW (HARROW INC) by 15.3% in shares. - Hold: The majority of the top holdings, including ETON (ETON PHARMACEUTICALS INC COM), URGN (UROGEN PHARMA LTD), APGE (APOGEE THERAPEUTICS INC), SLGL (Sol-Gel Technologies Ltd), RZLT (REZOLUTE INC), and TGTX (TG THERAPEUTICS INC). 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, with strategic additions and reductions. - Sector Bias: The healthcare sector is the clear bias, with 10 out of 11 top holdings in healthcare. - Risk Appetite: The fund exhibits a moderate risk appetite, with significant additions to high-growth potential companies but also reductions in certain positions. 4. Per-Holding One-Liner: - LQDA (LIQUIDIA CORPORATION): Develops and commercializes innovative therapies for serious diseases. - ETON (ETON PHARMACEUTICALS INC COM): Focuses on the development of treatments for central nervous system disorders. - HROW (HARROW INC): A biopharmaceutical company focused on the development of treatments for cancer. - IRON (DISC MEDICINE INC): Engages in the research and development of therapies for rare and orphan diseases. - URGN (UROGEN PHARMA LTD): Specializes in the development of therapies for urological conditions. - APGE (APOGEE THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - MGTX (MeiraGTx Holdings plc): Develops treatments for a range of ophthalmic diseases. - SLGL (Sol-Gel Technologies Ltd): Engages in the development and production of advanced materials and technologies. - RZLT (REZOLUTE INC): Specializes in the development of treatments for rare diseases. - TGTX (TG THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - Unverified: No unverified holdings noted. 5. One-Sentence Style Summary: The fund maintained a selective approach in healthcare, focusing on growth potential with strategic additions and reductions, while maintaining a cautious stance through sector concentration and selective adjustments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 90.2%
Materials 1.9%
Other 6.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.83M $99.86M 13.50%
13.50%
Reduce
2 2.54M $88.82M 12.01%
12.01%
Add
3 2.86M $70.58M 9.54%
9.54%
Hold
4 500.00K $39.61M 5.36%
Form 4 · 5 →
5.36%
Add
5 123.00K $35.32M 4.78%
4.78%
Reduce
6 390.00K $32.83M 4.44%
4.44%
Hold
7 421.00K $26.92M 3.64%
3.64%
Add
8 1.43M $25.71M 3.48%
3.48%
Add
9 1.31M $24.11M 3.26%
3.26%
Add
10 700.00K $22.79M 3.08%
3.08%
Add
11 6.30M $19.21M 2.60%
2.60%
Hold
12 2.12M $18.39M 2.49%
2.49%
Add
13 535.00K $17.77M 2.40%
2.40%
Hold
14 981.27K $16.97M 2.29%
2.29%
Hold
15 500.00K $15.75M 2.13%
2.13%
Hold
16 2.56M $14.07M 1.90%
Form 4 · 11 →
1.90%
Add
17 2.33M $12.92M 1.75%
1.75%
Reduce
18 550.00K $12.12M 1.64%
1.64%
Add
19 6.79M $11.06M 1.50%
1.50%
Hold
20 100.00K $10.54M 1.43%
1.43%
Reduce
21 100.00K $9.72M 1.31%
1.31%
Hold
22 300.00K $9.41M 1.27%
1.27%
Add
23 1.26M $8.06M 1.09%
1.09%
Add
24 260.00K $7.76M 1.05%
1.05%
Hold
25 935.00K $6.51M 0.88%
0.88%
Hold
26 94.80K $6.42M 0.87%
0.87%
Reduce
27 427.61K $6.01M 0.81%
0.81%
Hold
28 600.00K $5.08M 0.69%
0.69%
Reduce
29 265.71K $5.06M 0.69%
0.69%
Reduce
30 1.93M $4.76M 0.64%
0.64%
New
31 190.67K $4.75M 0.64%
0.64%
Hold
32 960.00K $4.50M 0.61%
0.61%
Reduce
33 1.15M $4.44M 0.60%
0.60%
Reduce
34 345.10K $4.12M 0.56%
0.56%
Hold
35 123.00K $3.80M 0.51%
0.51%
Reduce
36 1.38M $3.71M 0.50%
0.50%
Add
37 238.05K $3.45M 0.47%
0.47%
New
38 955.00K $3.42M 0.46%
0.46%
Hold
39 1.41M $3.31M 0.45%
0.45%
Add
40 245.00K $3.14M 0.42%
0.42%
New
41 1.04M $2.91M 0.39%
0.39%
Reduce
42 1.12M $2.25M 0.30%
0.30%
Hold
43 70.00K $1.89M 0.26%
0.26%
Hold
44 322.60K $1.74M 0.23%
0.23%
Add
45 79.10K $1.59M 0.21%
0.21%
New
46 125.00K $1.58M 0.21%
0.21%
Add
47 141.18K $1.51M 0.20%
0.20%
New
48 112.29K $1.05M 0.14%
0.14%
New
49 200.00K $834.00K 0.11%
0.11%
Reduce
50 340.00K $737.80K 0.10%
0.10%
Reduce

FAQ

What did Opaleye Management Inc. buy in 2026-Q1?

In its 2026-Q1 13F filing, Opaleye Management Inc. reported 53 equity positions worth $739.73M in aggregate; its largest disclosed positions were HROW ($99.86M), LQDA ($88.82M), ETON ($70.58M).

How large is Opaleye Management Inc.'s portfolio?

Opaleye Management Inc. reported $739.73M of long equity holdings across 53 positions as of 2026-Q1. Top-10 holdings account for 63.1% of reported value.

What is Opaleye Management Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/opaleye-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →